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DOI: 10.1039/b912493bNitric oxide (NO) is involved in several physiological processes, such as the control of vascular tone, the
inhibition of platelet aggregation, smooth muscle cell replication, the immune response, and wound
healing processes. Several pathologies have been associated with dysfunctions in the endogenous
production of NO. Thus, there is great interest in developing NO-releasing drugs and in matrices which
are able to stabilize and release NO locally and directly in different tissues. Over the past few years,
a very promising strategy for biocompatible NO-delivery systems has emerged based on the use of
nanobiotechnology for targeted NO-release for biomedical applications. In this work, the current state-
of-the-art approaches to NO-release from nanomeric materials, their preparation, and promising
biomedical applications are reviewed. Such materials, comprised of dendrimers, liposomes, metallic
and silica nanoparticles, polymeric micro and nanoparticles, semiconductor quantum dots, carbon
nanotubes, and nanoporous solid materials exhibit exceptional potential in directly delivering NO in
a controlled spatial and temporal manner with superior biocompatibility for pharmacological
applications.Introduction
Nitric oxide (nitrogen monoxide, NO) is a gas and free radical
with an unshared electron. It plays a key role in the regulation of
several physiological and pathophysiological processes, such as
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1624 | J. Mater. Chem., 2010, 20, 1624–1637tone, neurotransmission, glaucoma and neural degeneration,
vasodilation, pulmonary hypertension, penile erection, angio-
genesis, inflammation, immune response, septic shock, platelet
aggregation, gastrointestinal mobility, hormone secretion, gene
regulation, hemoglobin delivery of oxygen, stem cell prolifera-
tion and differentiation, bronchodilation, and wound healing.1–14
NO mediates its biological effects mainly by activating gua-
nylyl cyclase and increasing guanosine 30,50-cyclic mono-
phosphate (cGMP) synthesis from guanosine triphosphate
(GTP).15 However, many NO–cGMP-independent pathways
have been discovered recently.16 The endogenous synthesis of
NO is mediated through nitric oxide synthase (NOS) whichNelson Duran
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View Article Onlinecatalyzes the conversion of L-arginine to NO and citrulline.17
NOS is a homodimer with each monomer containing reductase
and oxygenase domains. The prosthetic groups are flavin adenine
dinucleotide (FAD), flavin mononucleotide (FMN), heme, and
the cofactors BH4 and Ca-calmodulin tetrahydrobiopterin.18 At
low concentrations, NO is quite stable and minimally reactive,
however, at higher concentrations, it can interact with transition
metals, heme-containing proteins, and thiol groups leading to the
oxidation of functional groups on RNA, DNA and proteins.19–23
In inflammatory processes, overproduced NO can rapidly react
with reactive oxygen species, such as superoxide (O2c
), to form
the very reactive peroxynitrite (ONOO), which can in turn
nitrate proteins.16 The biological effects of NO have been shown
to depend on the site and source of its production, as well as on
its concentration.
Many different classes of NO donors have been prepared






1,2-diolate (DETA/NO),25 S-nitrosoglutathione (GSNO) and
S-nitroso-N-acetylcysteine (SNAC),20,26–28,14 ruthenium deriva-
tives,29 and N-nitrosomelatonin (NOMela).30 These NO donors
can be incorporated into, or chemically linked to, biopolymers in
order to mimic the endogenous NO production directly at the
target site.26,31 Over the past few years, due to the wide range of
biological effects of NO, there has been a great effort to develop
agents that release NO in a controlled manner in living systems,
where it might have therapeutic effects.31 These NO-releasing
vehicles can be used in target tissues and sites of application to
modulate the in situ kinetics of NO release.26,28,31,32 Many vehicles,
such as NO donor complexes, have already been developed to
chemically store and release NO. Some of these compounds
include the thiol nitroso derivatives, the nitrosohydroxylamines,Fig. 1 Dendrimer synthesis (schematically depicted). Top: divergent strategy.
Royal Society of Chemistry).
This journal is ª The Royal Society of Chemistry 2010the nitrogen-bound diazeniumdiolates33,34 and the nitrosyl
ruthenium complexes that induce vasorelaxation.29
In order to increase the utility of NO release systems, current
research is aimed at coupling NO donors to nanoparticles. This
new and very promising area of research is named nano-
biotechnology. Pharmaceutical nanoparticle properties and drug
delivery from these materials have been widely studied in order to
increase their solubility, stability, and their specificity targets.35–37
The combination of NO donors with nanoparticles represents
a very promising strategy for the pharmaceutical applications of
NO. The aim of this feature is to review the latest strategies in
nanobiotechnology related to the biochemistry and clinical
medicine of NO donors in order to improve the biological
activities of NO for biomedical applications. Another area that is
leading to major improvement, but will not be discussed in this
mini-review, is the use of nanobiosensors for NO detection.38
The following are important nanostructures in the field of
nanobiotechnology related to NO release, which will be dis-
cussed in this review: dendrimers, liposomes, metallic and silica
nanoparticles, polymeric micro and nanoparticles, semi-
conductor quantum dots, carbon nanotubes, micellar nano-
assembly, and nanoporous solid materials.(a) Dendrimers
Dendritic architecture is found at the meter scale in tree
branching and roots, and at the centimeter and micrometer scales
in circulatory topologies of the human anatomy (e.g. lungs,
kidneys, liver, spleen, and cerebral neurons).39,40 Since nano-
structures are dendritic structures that include glycogen,
amylopectin, and proteoglycans,39 the resulting dendrimer
products are monodisperse compared to bulk polymers, and
their size (2–20 nm) varies with dendrimer type and exterior
functionality. The ‘‘divergent method’’, in which growth of
a dendron originates from a core site, was the first synthetic
strategy used to create dendrimers.41 This approach involvedBottom: convergent strategy (modified from ref. 40 by permission of The
J. Mater. Chem., 2010, 20, 1624–1637 | 1625
Fig. 2 The formation of sodium stabilized diazeniumdiolates
(NONOates) followed by decomposition under physiological conditions
to yield 2 mol of NO and initial dendrimer conjugate (n) 16, 64 (modified
from ref. 42 by permission of the American Chemical Society).
Fig. 3 Generation 4 polyamidoamine (PAMAM) dendrimers contain-
ing a completely modified exterior (64 thiols) of S-nitroso-N-acetyl-D,L-
penicillamine (G4-SNAP) or S-nitroso-N-acetylcysteine (G4-NACysNO)




























































View Article Onlineassembling monomeric modules in a radial, branch-upon-branch
motif according to certain dendritic rules and principles. The
second method followed a ‘‘convergent growth process’’ and
proceeded from what would become the dendrimer surface
inward to a reactive focal point, leading to the formation of
a single reactive dendron (Fig. 1).40
In accordance with this, the synthesis and characterization of
nanoparticle-NO-donors capable of storing and releasing large
quantities of NO from dendritic scaffolds have been reported
(Fig. 2).42
The primary advantage of NO-releasing dendrimers over other
vehicles is their high NO loading capacity per molecule of
dendrimer.42 In addition, it is possible to change the external
characteristic of the dendrimer, e.g. its solubility, or engineer it
for a specific function.40 For example, a dendrimer with a lipo-
philic external surface may be incorporated into hydrophobic
polymers to impart thrombo-resistivity to them, on the other
hand, hydrophilic dendrimers may allow for NO delivery in vivo.
Schoenfisch’s group42 has reported a new class of NO-releasing
macromolecules prepared from dendrimers functionalized with
primary and secondary amines. Secondary amine dia-
zeniumdiolates play an important role in the amine’s stability
since the total NO released from secondary amine conjugate
dendrimers is significantly greater than from the primary amine
dendrimers.42 Kinetic studies have shown that NO release from
dendrimer conjugates is proton initiated, which is consistent with
the mechanism of diazeniumdiolate dissociation. In this case, the
dendridic effect is demonstrated by the increased storage
capacity of this architecture and the half-lives of the NO donors
exceed, by several fold, those of the corresponding small mole-
cules.42 However, careful control of NO release is not possible
with diazeniumdiolate-modified dendrimers. Finally, the authors
suggest that the next step would be to introduce multiple func-
tionalities on the dendritic exterior to equip it with targeting
ligands (e.g., folic acid) to selectively deliver NO to cancer cells.42
S-nitrosothiols (RSNOs), such as S-nitrosoglutathione
(GSNO) and S-nitrosoalbumin, are the main carriers of NO
in vivo since they regulate several biological processes including
vasodilation, platelet activation, neurotransmission, and tissue
inflammation.43 RSNOs have been the subject of several studies
and pharmacological strategies addressing the importance of NO1626 | J. Mater. Chem., 2010, 20, 1624–1637in living systems. Several publications have shown the potential
therapeutic effects of RSNO adducts, including their toxicity
toward cancerous cells,44 their antimicrobial activity,20 their
cardioprotective effects during ischemia/reperfusion injury, and
their inhibition of platelet aggregation.45,46 One of the most
documented clinical applications of RSNOs is as antiplatelet
agents and inhibitors of platelet aggregation which do not affect
vascular tone.47 The drawback of these RSNOs is that they are
unable to deliver NO to a specific site of action. Additional
problems include thermal instability and their rapid systemic
clearance which have both seriously hindered the clinical devel-
opment of RSNO therapeutics.48 In order to partly avoid these
problems, Stasko et al.45 have reported the synthesis of two thiol-
derivatized generation 4 polyamidoamine (PAMAM) den-
drimers capable of storing up to 2 mmol NO mg1 of dendrimer
when converted to the corresponding RSNO-donors (Fig. 3).
The authors compared the antiplatelet aggregation effects of the
S-nitroso-N-acetyl-D,L-penicillamine dendrimer (G4-SNAP)
with those of free S-nitroso-N-acetyl-D,L-penicillamine (SNAP)
molecules in order to confirm the biological activity of the
dendrimer bound to RSNO. The G4-SNAP and the S-nitroso-N-
acetyl-L-cysteine (G4NACysNO) dendrimers stored and released
1.7  0.2 and 2.1  0.2 mmol NO mg1, respectively, in the
presence of initiators of RS-NO decomposition such as Cu2+ or
light.45
Since thiol groups present on the surface of platelets may
undergo trans-S-nitrosation reactions with RSNOs, the ability of
RSNO-dendrimers to cause the nitrosation of platelet surface
thiols leads to a careful control of NO release in biological
systems.45 Through the selective trans-S-nitrosation reaction
between the dendrimer-RSNO and thiol groups on the surface of
the platelets, the antiplatelet activity of G4-SNAP dendrimer was
45% more effective at preventing platelet aggregation than the
corresponding free SNAP (25 mM).45 Stasko and co-authors state
that one of the most important advantages of the dendritic
scaffold over other potential RSNOs drug delivery vehicles is the
easy and versatile functionalization of its exterior surfaces.45
Benini et al.49 have pursued the hypothesis that a similar
platform, previously reported by Stasko and Schoenfisch,42 could
be used for local and controlled delivery of NO using PAMAM
dendrimers functionalized with nitrosyl ruthenium complexes.
Benini and collaborators49 synthesized a K[RuIII(Hedta)Cl]This journal is ª The Royal Society of Chemistry 2010
Fig. 4 The preparation of a K[RuIII(Hedta)Cl] complex and its func-




























































View Article Onlinecomplex in which the EDTA ligand was pentadentate, with one
of the carboxylate arms unbound, and the sixth RuIII ligand was
a chloride ion. The presence of an uncoordinated carboxylate
allowed anchoring of the complex to the terminal amine groups
of PAMAM dendrimers through amide bonds (Fig. 4).
The PAMAM functionalized dendrimers with [RuII(edta)H2O]
are designated, for simplicity, as Gx/Ru, where x ¼ 0 (4 NH2
terminal groups), x ¼ 2 (16 NH2 terminal groups), and x ¼ 3
(32 NH2 terminal groups).
49 It is relatively easy to load NO to the
dendrimer Gx/Ru by purging NO gas with argon. As PAMAM
functionalized dendrimers with [RuII(edta)NO], designed as Gx/
RuNO, liberate NO when reduced in vivo and in vitro several
biological assays were performed to demonstrate the effects of
NO-releasing dendrimers. These experiments were carried out
using denuded normotensive rat aortic rings precontracted with
noradrenaline. The induction of slow, delayed relaxation was
initiated after 15 min and maximum relaxation was only achieved
after 37 min with Gx/RuNO (x ¼ 0 and 3.3 M).49 This behavior
was similar to that observed for [RuII(edta)H2O] (62 min) which
induced a slow, delayed relaxation with a maximum relaxation
effect in the second hour.50 The antitrypanosomal activity
showed that the G0/RuNO dendrimer was more effective against
T. cruzi (100%) than free [RuII(edta)NO] (89%).49Fig. 5 A compartmentalized nanocomposite material for light controlled
NO release. In the dark, NO is bound in the donor molecule, S-nitroso-
N-acetyl-D,L-penicillamine (SNAP), which cannot diffuse through the
liposome compartment membrane. The liposome is trapped within pores
of the silica cell culture substrate. Upon exposure to light the SNAP
controllably releases NO, which diffuses to the surface of the material.
(Reproduced from ref. 54 by permission of the American Chemical
Society.)(b) Liposomes
Liposomes have been used for carrying and delivering NO in
various biomedical applications.51 Phosphatidylcholine and
cholesterol, as well as positively and negatively charged lipids,
are used to prepare liposomes by a method that involvesThis journal is ª The Royal Society of Chemistry 2010hydration of the lipid film, sonication, followed by freezing and
thawing.52 NO incorporation into liposomes can be performed
by pressurizing the lipid dispersion with pure NO gas or NO
mixed with another gas, followed by a sonication step. Huang
et al.53 have reported that cationic liposomes provide the highest
NO delivery and incorporation (6 mL NO/mg lipids) into cells,
with rapid passive NO release in the first half hour, followed by
slow NO release for the next several hours. In addition, incu-
bating NO-releasing liposomes with cultured cells leads to an
increase in the production of intercellular guanosine 30,50-cyclic
monophosphate (cGMP) and the effective NO scavenger,
hemoglobin, does not affect NO activity. The authors demon-
strated that by incubating encapsulated NO with vascular
smooth muscle cells, the NO-bioactivity was preserved, even in
the presence of an NO scavenger.53
A recent work described the characterization of a novel NO-
releasing nanocomposite, wherein the NO release can be pho-
tostimulated and dynamically modulated at biological levels.54
The NO-releasing material was encapsulated within lipid vesicles
with a diameter of 150 nm and consisting of 1,2-dimyristoyl-
sn-glycero-3-phosphocholine (DMPC), cholesterol, and dihex-
adecyl hydrogen phosphate dissolved in chloroform. A thin lipid
film was formed on the walls of a glass vial and S-nitroso-N-
acetylpenicillamine (SNAP) solution at pH 6.0 with EDTA was
added and then extruded. Stimulation by a light source produces
an increased NO release from the nanocomposite material in
a very short period of time (Fig. 5).54 The NO release profile
decreases with distance perpendicular to the surface, as expected
for diffusion from a surface through an aqueous environment.
The authors found a linear relationship between NO surface
concentration and photon flux, and they suggest that this rela-
tionship can be used to tune the material’s response.54
Nanotechnology allied with NO-releasing materials can be
a useful tool in the treatment of coronary restenosis.55 WhenJ. Mater. Chem., 2010, 20, 1624–1637 | 1627
Fig. 6 A schematic view of the construction of the NO photocaging
monolayer-protected clusters (MPC-3) and mechanism for NO photo-




























































View Article Onlinecationic liposomes carrying plasmid DNA encoding inducible
and endothelial nitric oxide synthases (NOSi and NOSe,
respectively) are administered to human umbilical vein endo-
thelial cells (HUVEC) cultures with various inhibitors and
inducers of eNOS, the peripheral eNOS side effects must be
considered during clinical administration.56 Others researchers
have examined local iNOS plasmid application in injured
femoral and coronary artery models,57 and in the foxhound dog
model after an arterial graft.58 In vivo studies of eNOS plasmid
DNA formulated in cationic lipids and cholesterol have also been
carried out.59,60
Since a primary goal is to direct NO releasing compounds
(such as NONOates, i.e., compounds containing the N2O2-
group) to the infected cell, and thereby concentrate high levels of
NO near infectious agents, it has been hypothesized that lipo-
somes may facilitate this process since they are readily taken up
by macrophages.61 To determine whether liposomes would
enhance the uptake of these NONOates by macrophages, the
amount of NO released by macrophages after incubating these
cells with either liposome-encapsulated NONOates or non-
encapsulated NONOates was compared. The results demon-
strated that macrophages released 71% and 78% more NO after
exposure to liposomes (dimyristoylphosphatidylcholine
(DMPC) : dimyristoylphosphatidy-glycerol (DMPG) : choles-
terol, in mole ratios of 9 : 1 : 7.5) containing spermine/NO
(SPER/NO) and diethylenetriamine/NO (DETA/NO), respec-
tively, than macrophages treated with non-encapsulated SPER/
NO and DETA/NO.61permission of The Royal Society of Chemistry.)
Fig. 7 A synthesis scheme for the preparation of NO-releasing gold
nanoparticles (reproduced from ref. 69 by permission of the American
Chemistry Society).(c) Nanoparticles
(c.1) Metallic nanoparticles. Thiol-stabilized metal nano-
particles, monolayer-protected clusters, are hybrid systems for
bio-applications, and it is known that these small-sized surfaces
are easy to chemically modify by the introduction of functional
units. This has generated a large interest in their biomedicinal
applications.62–66
The design, fabrication, and properties of hydrosoluble plat-
inum nanoparticles decorated with the NO caging compound
monolayer-protected clusters (MPC-3) have been reported
(Fig. 6).63
Carboxy-terminated monolayer-protected clusters (MPC-1)
has been synthesized as a suitable scaffold for NO photoreleasing
nanoparticles (designed thiol 3, see Fig. 6).63 In this case, NO
photorelease takes place through a nitro-to-nitrite photo-
rearrangement followed by rupture of the O–NO bond with the
formation of NO and a phenoxy radical (see Fig. 6). The results
unambiguously showed that MPC-3 is stable in the dark and can
release NO upon irradiation with visible light. The biocompati-
bility of these nanohybrid systems and their potential in photo-
activated anticancer therapy have been explored in vitro using
tumor cell lines.63 HeLa cells exhibited negligible mortality in the
dark, accounting for the excellent biocompatibility between both
types of modified Pt nanoparticles. Results showed that cells
treated with MPC-3 were sensitive to light-induced death and the
extent of photoinduced cell mortality was strictly dependent on
the nanoparticle concentration.63
A recent report claims that gold nanoparticles catalyze NO
production from endogenous RSNOs in blood serum through1628 | J. Mater. Chem., 2010, 20, 1624–1637the formation of Au-thiolate on the surface of the gold nano-
particles.67 Furthermore, whenever the gold nanoparticles are
used in conjunction with a drug and its excipient as a probe in the
living body, caution must be taken to avoid causing oxidative
stress, since gold nanoparticles probably exert toxic effects on the
body via a dose-dependent increase in reactive nitrogen species
levels after treatment with the nanoparticles.67 This occursThis journal is ª The Royal Society of Chemistry 2010
Fig. 8 Strategy for diethylenetriamine (DETA) functionalization of tio-
monolayer-protected clusters (MPCs) by amide coupling, followed by
N-diazeniumdiolate formation (reproduced from ref. 33 by permission of




























































View Article Onlinebecause NO is known to react rapidly with superoxide to
produce the harmful peroxynitrite (ONOO) species, which
easily interacts with lipids, DNA, and proteins via direct oxida-
tive reactions or indirectly causing radical-mediated damage.67,68
The monolayer-protected gold cluster nanoparticles are very
small in size (1–5 nm), have high stability, and are easily func-
tionalized.69 The metallic nanoparticle surfaces are easily altered
by thiols containing the desired functional groups. The charac-
teristics of these gold nanoparticles, as described above, could
prove useful for a wide range of biomedical and pharmaceutical
applications (e.g., in vivo sensor design, topical creams for wound
healing, and/or the dilation of blood vessels) (Fig. 7).69
Water-soluble NO-releasing monolayer-protected gold clus-
ters with tiopronin (3 nm) were functionalized with amineFig. 9 The synthesis of N-diazeniumdiolate-modified silica nanoparticles
trimethoxysilane (AHAP3) as tetraalkoxy- and aminoalkoxysilane precurso
Society).
This journal is ª The Royal Society of Chemistry 2010ligands and subsequently exposed to 5 atm of NO gas to form
diazeniumdiolate NO donors covalently bound to the gold
cluster.33 Unfortunately, these particles did not efficiently store
NO (<0.023 mmol mg1), therefore to increase the NO storage
capacity of these gold nanoparticles, polyamine-stabilized gold
clusters (5 nm) (pentaethylenehexamine-PEHA) were synthe-
sized and exhibited significantly enhanced NO-release
(0.386 mmol mg1) (Fig. 8).33
(c.2) Silica nanoparticles. The synthesis of a new NO-releasing
scaffold prepared from amine-functionalized silica nanoparticles
was initiated through inorganic–organic hybrid silica and
prepared via co-condensation of tetraethoxy- or tetramethoxy-
silane and aminoalkoxysilane with ethanol (or methanol), water,
and ammonia.70 Afterwards, the amine functional groups in the
silica were converted to the NO donor N-diazeniumdiolate via
exposure to high NO pressures under basic conditions (20–
500 nm) with NO payloads of 50–1780 nmol mg1 (Fig. 9).70
Shin et al.70 have pointed out that the diversity of NO release
kinetics, scaffold size, and favorable toxicity represent the
distinct advantages of silica over previously reported nano-
particle systems. Based on the capacity to tune NO storage and
release and the small size of the silica nanoparticles, this material
could be important in new NO-based therapies.70 Silica nano-
particles prepared using the pre-formation approach exhibited
an up to 6–7 fold greater NO payload and NO release duration
than silica synthesized via a post-formation method.71
The same group has reported the synthesis of dia-
zeniumdiolate-modified aminoalkoxysilanes prior to nano-
particle formation, in which particle aggregation was reduced
due to decreased hydrogen bonding interactions between amines
during particle formation.72 The synthesis resulted in 99% amine-
to-diazeniumdiolate conversion efficiency and greater yields of
NO per mole of aminoalkoxysilane precursor compared to
previous synthetic procedures used to generate NO-releasing
silica nanoparticles (Fig. 10).72
The bactericidal efficacy of the 45 mol% N-(6-aminohexyl)
amino-propyltrimethoxysilane (AHAP3) NO-releasing silica
nanoparticles has been evaluated against P. aeruginosa, and has
been shown to be significantly more effective than NO released
from the small molecule NO donor.72 In vitro cytotoxicity
experiments with fibroblasts have confirmed that NO-releasing
silica nanoparticles are largely nontoxic to these cells at
concentrations capable of killing P. aeruginosa.72
NO-releasing fumed silica particles (0.2–0.3 mm) have been
synthesized by tethering alkylamines onto the silica surface usingusing tetramethoxysilane (TMOS) and N-(6-aminohexyl)aminopropyl-
rs (reproduced from ref. 70 by permission of the American Chemical
J. Mater. Chem., 2010, 20, 1624–1637 | 1629
Fig. 10 The synthesis of N-(6-aminohexyl)aminopropyltrimethoxysilane
(AHAP3) NO donors and co-condensation with tetraethoxysilane (TEOS)
to form NO-releasing silica nanoparticles: R ¼ –(CH2)3Si^ and R0 ¼





























































View Article Onlineamine-containing silylation reagents, which are converted to the
corresponding N-diazeniumdiolate groups upon reaction with
NO gas at high pressure in the presence of methoxide bases
(Fig. 11).73 It has also been shown that the resulting NO-releasing
fumed silica particles can be embedded in polymer films, creating
coatings that are thrombo-resistant, due to NO release at fluxes
that represent normal endothelial cells. A polyurethane coating
containing 20 wt% of NO-releasing particles prepared with
a pendant hexane diamine structure (i.e., Sil-2N[6]-N2O2Na)Fig. 11 The synthesis route to Sil-N2O2M particles (reproduced from
ref. 73 by permission of the American Chemical Society).
1630 | J. Mater. Chem., 2010, 20, 1624–1637exhibited improved surface thrombo-resistivity in a rabbit
model.73
(c.3) Polymeric micro and nanoparticles. Due to its biocom-
patibility and biodegradability, poly-lactic-co-glycolic acid
(PLGA) is approved for therapeutic use by the Food and Drug
Administration (FDA).74 PLGA is one of the most widely used
polymers for preparing micro and nanoparticles35,75 and a PLGA
microparticle encapsulated with the NO pro-drug diethylenetri-
amine/NONOate (DETA/NONOate) has been produced. PLGA
microparticles can protect the pro-drug from dissociation under
acidic conditions and promote controlled release of NO, which is
useful for medical applications, e.g. vaginal-specific delivery of
NO.76 The microparticles were fabricated using various solvent
evaporation/extraction techniques, such as water in oil in oil
(W/O/O)], followed by freeze-drying (20 mm). The effects of
microparticle fabrication conditions as well as particle size
distribution, morphology and drug entrapment efficiency were
also investigated. In vitro NO release studies performed at
vaginal pH (pH 4.0) revealed that PLGA 50/50 microparticles
produced by W/O/O (36% loading) released NO over 14 h
following an initial burst of 50% NO released within 30 min.76
In addition to PLGA encapsulated with NONOates, Tfouni’s
group77 reported the synthesis and characterization of the
ruthenium nitrosyl complex (trans-[Ru(NO)(NH3)4(py)](BF4)3

H2O), loaded into a polymeric PLGA microparticle (0.9–6.0 mm)
using a double emulsification method. The choice of loading
conditions was dictated by the characteristics of both the
ruthenium nitrosyl complex and the microparticle matrix. At
concentrations lower than 1  104 M, the nitrosyl complex did
not show toxicity in B16–F10 murine cells, whereas, free in
solution it was toxic at higher concentrations (>1  103 M),
with cell death attributed to NO release following the reduction
of the complex.77 The nitrosyl complex was not cytotoxic in the
dark, however it was upon light irradiation. This phototoxicity
suggests that cell death is due to NO release from the complex.
This model proposes an interesting system for carrying and
locally delivering NO, under irradiation, to tumor cells.77
Similar to Tfoni’s group77,78 Mascharak’s group79–81 has also
been investigating metallic complexes in biocompatible poly-
meric materials that photorelease NO for specific clinical appli-
cations. For example, Eroy-Revels et al.80 reported the NO
release with high quantum efficiency upon irradiation with
visible light of a sol–gel hybrid material containing the photo-
active manganese nitrosyl, [Mn(PaPy3)(NO)]ClO4. The NO-
releasing sol–gel material was coated with the biocompatible
polyurethane to enhance the material’s stability in biological
fluids. An advantage of this material is the rapid generation of
NO upon irradiation with visible light at specific sites of action
where NO might have biological effects, such as the induction of
tumor cell death in photodynamic therapy.82 As reported in these
works, photochemical NO-release materials play an important
role in the photodynamic therapy.80,82
Chitosan is another broadly biodegradable and biocompatible
polymer that can enhance the transport of polar drugs across
epithelial surfaces for several biomedical applications.83 Diethyl-
enetriamine (DETA) and propionic aldehyde (PA) were
employed individually to modify the primary amine groups on
chitosan. Two diazeniumdiolates (chitosan/NO adducts) wereThis journal is ª The Royal Society of Chemistry 2010




























































View Article Onlineprepared by suspending the chitosan derivatives in a sodium
methoxide–methanol solution under 6 atm of NO for seven
days.84 The NO release profiles of the chitosan derivatives in PBS
(pH 7.4, 37 C) were investigated by the Griess assay. The results
show that increased nucleophilic sites on DETA-modified chi-
tosan results in high NO loadings, and the maximal NO release
from chitosan/DETA/NO and chitosan/PA/NO was 1945 nmol
mg1 and 1156 nmol mg1, respectively.84
(c.4) Other nanoparticles. Nanotechnologies applied to NO
action have led to the creation of a novel approach that
successfully inhibited neointimal hyperplasia in a rat carotid
artery injury model.24 The diazeniumdiolates evaluated in this





amino] diazen-1-ium-1,2-diolate (DETA/NO) (Fig. 12).24 Among
the studied gels, disodium 1-[(2-carboxylato)pyrrolidin-1-yl]dia-
zen-1-ium-1,2-diolate (PROLI/NO) nanofiber gel was the most
effective neointimal hyperplasia inhibitor. The authors are aware
that before this new therapy can be used in clinical procedures,
the toxicity as well as the efficacy of NO-releasing micro and
nanopaticles must be evaluated in long-term studies using
a large-animal model. All the facts indicate that this novel NO-
based therapy has promising clinical potential, and its use in
vascular and cardiovascular surgical procedures to prevent
restenosis and the associated patient morbidity appears possible
in the near future.24
Recently, a report revealed that a hydrogel/trehalose
composite with NO is composed of nanosized building blocks
that show varying degrees of aggregation.85 This structure
allowed the generation of NO through the thermal reduction of
added nitrite by glucose after exposure of these robust biocom-
patible nanoparticles to moisture, leading to the initiation of
sustained release of the trapped NO over an extended period of
time. Nitrite-containing glassy matrices were prepared in
a phosphate-buffered (pH 7.5) sodium nitrite solution and the
sugars were then added. It was estimated that each nanoparticle
was about 10 nm in diameter comprising aggregates.85 Compared
with the control particles, fibroblasts treated with NO-releasing
hydrogel/glass composite particles exhibit minimal toxicity.
These results support the use of these nanoparticles in vivo and
demonstrated their potential as biocompatible therapeutics. The
authors state that these new NO-releasing nanoparticles can be
easily designed for different therapeutic circumstances.85
Photochemical NO release from biomaterials is an important
tool for controlled release of NO in biomedical applica-
tions.54,63,86 A recent review86 covers the preparation andThis journal is ª The Royal Society of Chemistry 2010photochemistry of a series of transition metal complexes
designed to release NO upon visible or near infrared excitation,
including the works of Tfouni’s,77,87 Mascharak’s88 and Neu-
man’s groups (the latter with quantum dots).89,90 In particular,
semiconductor quantum dots (QDs) nanocrystals ( 2–100 nm)
represent an attractive class of materials, since they are currently
used as fluorophores in biomedical applications.91 QDs are
capable of enhancing photochemical NO production from elec-
trostatic assemblies due to their high extinction coefficients.89 An
advantage of QDs is their functionalization can lead to attach-
ment of key molecules at the nanocrystal surface to improve their
water solubility and/or stability and biological specificity.92 Such
functionalization can also be used to incorporate NO precursors
or carriers. Neuman et al.89,90 describe the energy-transfer
processes between water-soluble core/shell CdSe/ZnS QDs and
the cationic complex, trans-Cr(cyclam)(ONO)2
+. They observed
an increase in the photoproduction of NO from the transition
metal centers in the presence of CdSe/ZnS core-shell QDs. This
is evidence for electron and/or energy transfer from QDs to
nearby molecules capable of generating important radical species
such as NO.
However, metals such as cadmium and selenium, two of the
most widely used metals in QD core metalloid complexes, are
known to be acutely and chronically toxic in vertebrates and are
of considerable human health and environmental concern.93,94
QDs may pose risks to human health and to the environment,
and the toxicity of these materials needs to be carefully evaluated
for biomedical applications.93(d) Carbon nanotubes
Carbon nanotubes can be used for the release of NO at target
sites. In this context, silver-gold bimetallic nanoparticles were
prepared, as reported by Alvarez-Puebla et al.,95 by the citrate
reduction method and silver ions, followed by titration with
HAuCl4 solution (Fig. 13).
Next, multiwalled carbon nanotubes (5 nm diameter, 5–20 mm
in length, and 95% purity) were sonicated at pH 10 in a solution
containing NaCl and poly(allylamine hydrochloride)(PAH)
forming CNTs@PAH.96 The intermediate sample CNTs@PAH
was reacted with a bimetallic nanoparticle suspension under
sonication forming the CNT@AuAg hybrid colloid. The influ-
ence of gold on NO formation at physiological pH was studied
by mixing a nitrosothiol solution with the CNT@AuAg hybrid
colloid, where a RSNO bond was immediately cleaved due to the
high affinity of gold for thiols, liberating NO (Fig. 14).96 It has
also been demonstrated that metal nanoparticles adsorbed onto
carbon nanotubes can be used as a trigger for the generation of
NO from an external RSNO.96J. Mater. Chem., 2010, 20, 1624–1637 | 1631
Fig. 13 Transmission electron microscopy images of (A) silver citrate
colloids, and (B) silver citrate colloids treated with 15 mL of 103 M gold
solution. (Reproduced from ref. 95 by permission of the American
Chemical Society.)
Fig. 14 A carbon nanotube containing RSNO as NO donor. (Modified




























































View Article OnlineIt is known that irradiation of a metal-nitrosyl complex causes
NO release when the appropriate wavelength of light is used.87,88
This is one of the reasons why metal-nitrosyl complexes are used
in photodynamic therapy to kill cancer cells.86 However, it is
difficult to find a combination that has a safe wavelength for the
body as well as a fast NO release. One interesting approach is to
functionalize the surface of a multiwalled carbon nanotube with
a Ru–NO complex. This is possible since the nanotube can
absorb light and transfer it to the ruthenium moiety, causing the
release of NO. This approach aims to quickly release NO using
light in the visible range rather than the ultraviolet one.97(e) Micellar nanoassembly
Caruso et al.,98 have reported the preparation of a photoactive
micellar nanoassembly system, for cancer therapy, that controls
the simultaneous release of NO and singlet oxygen upon stimu-
lation with visible light. Fig. 15 shows the multifunctional1632 | J. Mater. Chem., 2010, 20, 1624–1637micellar nanoassembly, which is composed of mesogen-bearing
cationic amphiphilic N,N,N-trimethyl-10-{[4-nitro-3-(trifluoro-
methyl)phenyl]amino}decan-1-aminium bromide (compound 1,
Fig. 15) and the anionic 5,10,15,20-tetrakis(4-sulfonatophenyl)-
21H,23H-porphyrin (TPPS) that releases NO and singlet oxygen
under excitation at 450 nm and 532 nm, respectively. The
photorelease of NO involves a nitro-to-nitrite rearrangement
followed by the rupture of the O–N bond, generating NO and
phenoxyl radical. The authors believe that the extension of this
approach using a variety of ad-hoc-chosen NO photodonors and
porphyrin derivatives may facilitate the route for the develop-
ment of novel classes of nanoscaled, photoactive systems in
nanomedicine.98(f) Nanoporous solid materials
Nanoporous solid materials such as zeolites and metal–organic
frameworks with a variety of architectures and chemical
composition have been recently considered as one of the most
promising vehicles in nanotechnology for releasing NO in
medical applications.99 This is based on the fact that these
nanoporous solid materials are able to absorb, store, and release
free NO in a controlled manner. Zeolites are highly crystalline
aluminosilicate microporous materials with a rigid three-
dimensional network of channels, cages and rings that share
corners to produce an open framework, which is ideal for the
adsorption of small gaseous molecules, such as NO.100
Exposure of zeolites to NO gas results in both reversible and
irreversible NO adsorption. Reversibly adsorbed NO is consid-
ered to be physisorbed and NO is readily released while irre-
versibly adsorbed NO is not spontaneously released, since it
interacts strongly with extraframework cations in these porous
materials.99,101 Due to the high affinity between NO and zeolites,
zeolites absorb and store NO in high capacity (up to ca. 3.5 mmol
of NO per g of zeolite),102 and it has been reported that NO-
loaded zeolites are stable in the anhydrous state for several
months and even more than one year.99 NO can be released in
biologically relevant amounts to target sites upon contact with
water, making this an attractive approach for long-term NO
storage. A major advantage of using zeolites as NO-delivery
vehicles is that the rate of NO release can be modulated and
tailored to the desired range for medical applications by altering
the metal-ion content and structure of the zeolites, as well as the
vehicle containing the zeolite. It has been reported that the total
amount of NO released is approximately 1 mmol of NO per g of
zeolite,100 and an initial short-lived burst of NO release followed
by slower release was observed.102
Biological assays with NO-containing zeolites showed that
they inhibit platelet aggregation and the adhesion of human
platelets in vitro making zeolite-containing materials good
candidates for the prevention of thrombus formation.100 Fig. 16
shows scanning electron micrographs of the surface of pressed
disks of Co-zeolite in 75 : 25 wt% mixtures with powdered poly-
(tetrafluoroethylene) (PTFE) (a) untreated and (b) NO-loaded
Co-zeolite/PTFE disks. Fig. 16 (a) shows the presence of platelet
aggregates (PA) on the surface of zeolite/PTFE (Z/PTFE) while
only a reduced number of platelets (P) can be observed on the
surface of NO-loaded zeolites/PTFE (NO-Z/PTFE) (Fig. 16
(b)).100 Recently, Mowbray et al.103 reported that the topicalThis journal is ª The Royal Society of Chemistry 2010
Fig. 15 Micellar nanoassembly for the photorelease of NO and singlet oxygen upon stimulation with visible light. (Reproduced from ref. 98 by
permission of The Royal Society of Chemistry.)
Fig. 16 Scanning electron micrographs of the surface of pressed disks of
Co-zeolite in 75 : 25 wt% mixtures with powdered poly(tetrafluoro-
ethylene) (PTFE) (a) untreated and (b) NO-loaded Co-zeolite/PTFE
disks. The presence of large platelet aggregants (PA) on the surface of
zeolites/PTFE disks can be observed in (a), while in (b) there are a few
platelets on the surface of NO-loaded zeolites/PTFE disks. (Reproduced




























































View Article Onlineapplication of NO-containing zeolites increased dermal blood
flow in humans. The enhanced flow was correlated with trans-
dermal NO diffusion through the skin as assayed by cutaneous
microdialysis.103 NO released from the zeolites was able to diffuse
across the epidermis and dermis to promote the local vasodilation
with minimal pro-inflammatory effects, making NO-releasing
zeolites good candidates for dermatological applications (such as
the promotion of wound healing and treatment of cutaneous
fungal and viral diseases).
In addition to zeolites, metal organic frameworks (MOFs), or
porous coordination polymers, are crystalline nanoporous
materials comprised of a metal or metal clusters connected three-
dimensionally by organic linkers. NO can be strongly absorbed
at the metal sites, and the substitution of NO by water promotesThis journal is ª The Royal Society of Chemistry 2010NO release from the MOFs, similar to NO release from
zeolites.99,101 Moreover, the preparation of MOFs and zeolites
that contain copper(I) species (CuI) has been reported.104 These
materials offer an additional advantage as NO donors, since CuI
catalyzes the biotransformation of nitrite to NO; hence the
amount of NO produced is enhanced by catalytic gas produc-
tion.104
Again, by changing the composition and structure of the MOF
it is possible to control the rate of NO release and adjust it for the
desired biological application. For example, a low flux of NO is
required for anti-thrombogenic applications (typically 1 
1010 mol cm2 min1)105 while higher doses are necessary for
anti-bacterial effects.106 Upon exposure to moisture, MOFs can
release ca. 7 mmol NO per g of material,101 and the NO released
from MOFs was found to inhibit platelet aggregation107 and
promote relaxation of porcine arteries.101
Since zeolites and MOFs contain transition metal ions, the
potential toxicity of the metals to biological systems is of
concern.107 For example, NO-releasing zeolites or MOFs when in
contact with biological fluids such as blood, will lose their metal
ions. Therefore, further studies are needed before these materials
can be considered as NO donors, in practice.(g) Patents and innovations
Many patents describe inventions using nanotechnology in
combination with NO donors. The storage and release of NO
from these donors has been considered a great challenge in
medically-relevant situations, in part due to the gaseous nature of
NO and its instability in the presence of oxygen. A patent by
Toone and Stamler108 provided a method of preparing some NO-
releasing nanomaterials, particularly those comprising carbon
nanotubes, containing NO or gases with NO-like biological
activity, where the gas is non-covalently bound to the compound.
These compounds allow for the storage of NO gas, followed by
its controlled release. Compounds disclosed in the invention
include polymers, articles, pills, capsules, and medical devices.108J. Mater. Chem., 2010, 20, 1624–1637 | 1633
Fig. 17 The chemical structure of S-nitroso-N,N,N-trimethylsphingo-




























































View Article OnlineAnother interesting patent reported liposome formation with
lipids containing (a) an S-nitroso moiety –S–N]O, (b) an O-
nitroso moiety –O–N]O, and/or (c) an N-nitroso moiety, and the
preferred N-nitroso groups included the NONOates.109 As
a specific example, S-nitroso-N,N,N-trimethylsphingosine was
synthesized by first adding a thiol group to one or more of the
hydroxyl groups of N,N,N-trimethylsphingosine, and subse-
quently S-nitrosating the thiol. Upon delivery to the body (e.g., to
the vasculature) the S-nitroso-N,N,N-trimethylsphingosine of the
present invention released NO, which has numerous beneficial
therapeutic effects. Since it contains N,N,N-trimethylsphingosine
(Fig. 17), this compound also inhibits platelet formation and
prevents leukocyte-endothelial interactions, even after the release
of NO from the compound.109 One advantage of the described
S-nitrosated, N-nitrosated and O-nitrosated lipids over other
organic and inorganic NO donors is that they can be readily
incorporated into cell membranes, promoting tissue uptake and
enhancing tissue retention time. Similarly, these S-nitrosated,
N-nitrosated and O-nitrosated lipids have an affinity for lipid
deposits in the body, such as those within atherosclerotic plaques.
This affinity allows for targeted NO release within such regions.109
Recently, another patent has described the synthesis of
biodegradable and non-biodegradable nanoparticles for coating
medical devices, such as intracoronary stents.110 The nano-
particles are composed of a matrix and a bioactive agent, wherein
the matrix or shell is formed of a material selected from ceramic
materials, bioglass, metals, polymers, plastic, and combinations
thereof. The bioactive agent is selected from many active drugs
and in particular, NO donors. One method for treating
a disorder in a patient consists of implanting the nanoparticle-
releasing medical device, wherein the disorder is selected from,
for example, atherosclerosis, thrombosis, restenosis, hemor-
rhage, vascular dissection or perforation, vascular aneurysm,
vulnerable plaque, etc.110
In another patent, Trescony et al.111 have described the prep-
aration of a biodegradable polymer matrix impregnated with an
NO donor for continuous release of NO upon hydration. In this
context, poly(L-lactic acid)-CCl4 containing a solution of NaNO2
in MeOH is used to coat stents or polyurethane tubing for slow
release of NO as the polymer degrades in test systems. The
polymer matrix provides an acidic microenvironment that facil-
itates the conversion of organic or inorganic nitrite to NO. Poly-
lactic acid slowly biodegrades to lactic acid, which facilitates the
conversion of nitrite to NO. The invention also provides
a material capable of releasing NO for use in the lining of blood-
contacting surfaces of implantable or extracorporeal devices, so
as to reduce or eliminate the undesired effects of platelet aggre-
gation or thrombogenesis. Additionally, in situ production and
release of NO avoids the problems associated with the short half-
life of NO under physiological conditions.1111634 | J. Mater. Chem., 2010, 20, 1624–1637Schoenfisch et al.112 published an invention that included at
least one NO donor in combination with a second therapeutically
active agent (e.g., silver nanoparticles) with antimicrobial and
wound healing capability. As a result, a patient may benefit from
reduced dosage requirements and therefore a reduced likelihood
of developing antimicrobial resistance. The compound can be
formulated for local or systemic administration, for topical
applications, as well as for use in coatings for medical supplies and
devices.112 In another patent, Russell et al.113 proposed the use of
NO-releasing zeolites for medical applications such as the inhi-
bition of platelet aggregation to prevent thrombus formation.(h) Toxicological evaluation of NO nanodonors
A crucial issue with regards to the clinical use of NO-releasing
materials is the lack of a complete evaluation of their toxicity in
vivo, and this applies to most of the vehicle types previously
mentioned in this review. Clearance of the vehicle after NO
release in biological systems must also be characterized since the
majority of NO-releasing materials (dendrimers, metallic nano-
particles, QDs, carbon nanotubes, and nanoporous solid mate-
rials) contain metals in their structure, which can lead to toxicity
in vivo. As an example, the two most widely used metals in QDs,
cadmium and selenium, are known to cause acute and chronic
toxicity in vertebrates.93,94 Therefore, before these materials can
be proposed for use in clinical applications, the crucial issue of
their short- and long-term toxicity must first be extensively
characterized and evaluated.Summary and conclusions
Due to the crucial effects of NO as an endogenous mediator of
numerous physiological processes in the cardiovascular, immune
and nervous systems, and also in skin physiology, great effort has
been devoted to the development of NO delivery systems for
therapeutic purposes in the last few years, as reported by Miller
and Megson.34 Biomaterials that act as NO carriers and release
NO in a controlled manner are highly desirable for biomedical
applications. Recently, considerable improvement in the devel-
opment of NO-releasing vehicles was made by combining
nanotechnology and NO-delivery systems. The success of this
new strategy is based on the fact that nanotechnology allied to
NO delivery can overcome many of the main challenges in NO-
donor therapy: generation of the desired amount of NO, for the
right length of time, at the target location.
The advantage of NO-releasing dendrimers is not only that
these nanoparticle-NO-donors are able to store and release large
amounts of NO,42 but also the exterior surface of the dendritic
scaffold can be functionalized to improve the material’s solu-
bility or engineer it for a specific function.45 This latter advantage
is important since chemical modification of the material’s surface
should allow delivery of NO selectively to target cells or tissues.
However, as stated by Schoenfish’s group,42 a disadvantage of
this vehicle is the difficulty in controlling the NO release from
diazeniumdiolates-modified dendrimers. NO control is extremely
important for the biological applications of these materials,
especially in the cardiovascular arena. In addition, the synthesis
of dendrimers is not simple, and it involves the addition of




























































View Article Onlineincorporate and deliver high amounts of NO.61 An advantage of
these vehicles is that liposomes have been used in dermatological
applications due to their biocompatibility.51
A major advantage of metallic nanoparticles, such as the
monolayer-protected gold cluster, are their small size (1–5 nm),
high stability and ease of surface functionalization.62–66 More-
over, these materials can release NO upon irradiation, allowing
their use as photoactive materials in medical applications, such
as in anticancer therapy.63 As pointed out by Shin et al.,70 silica
nanoparticles offer some advantages in terms of NO release
kinetics, scaffold size, and lower toxicity over previously
designed nanoparticle materials for NO release.
A positive aspect of polymeric micro- and nano-particles is
that these materials are often comprised of the biologically
friendly, FDA approved polymer poly-lactic-co-glycolic acid
(PLGA).74,75 Furthermore, PLGA micro particles protect the
pro-drugs from dissociation and are able to control NO release.
However, the preparation of these materials is expensive and for
pharmaceutical applications the cost of micro- and nano- particle
production should be lowered. PLGA can encapsulate different
classes of NO donors, such as NONOates76 and ruthenium
nitrosyl complexes,77 and release NO in a controlled manner
upon irradiation. NO-releasing nano-particles are very prom-
ising materials for biomedical applications.
Transition metal complexes have been successfully used for
controlled NO release under irradiation with visible light.54,63,86
Among these materials, semiconductor quantum dot nanocrytals
(QDs) offer the advantage of enhanced photochemical NO
production from electrostatic assemblies.89 Similar to den-
drimers, QDs have multiple coordination sites on their surface to
impart properties such as solubility, biological specificity, and to
attach NO precursors.89,92
Carbon nanotubes can be decorated to improve NO release in
biological applications. For example, metal nanoparticles96 or
Ru–NO complexes97 adsorbed onto the nanotube surface can
release NO upon irradiation with visible light.
Finally, nanoporous solid materials such as zeolites and
metal–organic frameworks are very promising vehicles for NO
release in pharmacological therapies due to their very rich
chemistry and architecture.99–104 These materials can absorb large
amounts of NO, store the gas for over a year and release free NO
without other by-products. In addition, these materials exhibit
NO bioactivity and recently the dermatological application of
NO-releasing zeolites in humans increased dermal blood flow
due to NO diffusion across the skin with minimal inflammatory
response, making these materials highly desirable candidates for
dermatological applications of NO-therapy.
In summary, it is clear from the recent literature that nano-
technology will, in the very near future, enhance the application
of NO in several medical disorders in which this biologically
important molecule is needed. The combination of nanotech-
nology with NO chemistry and biochemistry to create efficient
NO-releasing therapies that can be used clinically offers great
promise in medicine.
The design of NO-delivery vehicles can be considered
advanced in terms of the preparation of new, versatile and
different classes of materials. Generally, these materials are able
to load high amounts of NO, are quite stable, some are photo-
active, their surfaces can be chemically modified and optimizedThis journal is ª The Royal Society of Chemistry 2010for specific medical applications, and all of them possess
demonstrable biological activity. Most materials release NO over
an hour, which is useful for short-term NO therapy. However,
for some medical applications, long-term NO release is neces-
sary. For example, there is a great interest in NO-releasing blood-
compatible polymeric materials for coating medical devices such
as intravascular catheters, vascular grafts, coronary artery and
vascular stents, and long-term vascular access devices. In these
cardiovascular applications, continuous NO release over days
and even months is desired.
Of course, each technology presented in this review offers
advantages and disadvantages. However, the vehicle that proves
to be highly efficient in NO delivery, releases NO for longer
periods of time, and be fully biocompatible will, undoubtedly,
find success in practical medical applications. Additionally, the
therapy should be simple to perform, economically feasible,
safe, and without side-effects. To this end, we need specific
regulations and control of these new nanomaterials for their use
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